Outpatient glycemic control with a bionic pancreas in type 1 diabetes
- PMID: 24931572
- PMCID: PMC4183762
- DOI: 10.1056/NEJMoa1314474
Outpatient glycemic control with a bionic pancreas in type 1 diabetes
Abstract
Background: The safety and effectiveness of automated glycemic management have not been tested in multiday studies under unrestricted outpatient conditions.
Methods: In two random-order, crossover studies with similar but distinct designs, we compared glycemic control with a wearable, bihormonal, automated, "bionic" pancreas (bionic-pancreas period) with glycemic control with an insulin pump (control period) for 5 days in 20 adults and 32 adolescents with type 1 diabetes mellitus. The automatically adaptive algorithm of the bionic pancreas received data from a continuous glucose monitor to control subcutaneous delivery of insulin and glucagon.
Results: Among the adults, the mean plasma glucose level over the 5-day bionic-pancreas period was 138 mg per deciliter (7.7 mmol per liter), and the mean percentage of time with a low glucose level (<70 mg per deciliter [3.9 mmol per liter]) was 4.8%. After 1 day of automatic adaptation by the bionic pancreas, the mean (±SD) glucose level on continuous monitoring was lower than the mean level during the control period (133±13 vs. 159±30 mg per deciliter [7.4±0.7 vs. 8.8±1.7 mmol per liter], P<0.001) and the percentage of time with a low glucose reading was lower (4.1% vs. 7.3%, P=0.01). Among the adolescents, the mean plasma glucose level was also lower during the bionic-pancreas period than during the control period (138±18 vs. 157±27 mg per deciliter [7.7±1.0 vs. 8.7±1.5 mmol per liter], P=0.004), but the percentage of time with a low plasma glucose reading was similar during the two periods (6.1% and 7.6%, respectively; P=0.23). The mean frequency of interventions for hypoglycemia among the adolescents was lower during the bionic-pancreas period than during the control period (one per 1.6 days vs. one per 0.8 days, P<0.001).
Conclusions: As compared with an insulin pump, a wearable, automated, bihormonal, bionic pancreas improved mean glycemic levels, with less frequent hypoglycemic episodes, among both adults and adolescents with type 1 diabetes mellitus. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; ClinicalTrials.gov numbers, NCT01762059 and NCT01833988.).
Figures
Similar articles
-
Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.Lancet Diabetes Endocrinol. 2016 Mar;4(3):233-243. doi: 10.1016/S2213-8587(15)00489-1. Epub 2016 Feb 3. Lancet Diabetes Endocrinol. 2016. PMID: 26850709 Free PMC article. Clinical Trial.
-
Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.Lancet. 2017 Jan 28;389(10067):369-380. doi: 10.1016/S0140-6736(16)32567-3. Epub 2016 Dec 20. Lancet. 2017. PMID: 28007348 Free PMC article. Clinical Trial.
-
Nocturnal glucose control with an artificial pancreas at a diabetes camp.N Engl J Med. 2013 Feb 28;368(9):824-33. doi: 10.1056/NEJMoa1206881. N Engl J Med. 2013. PMID: 23445093 Clinical Trial.
-
Current topics in glycemic control by wearable artificial pancreas or bedside artificial pancreas with closed-loop system.J Artif Organs. 2016 Sep;19(3):209-18. doi: 10.1007/s10047-016-0904-y. Epub 2016 May 3. J Artif Organs. 2016. PMID: 27142278 Review.
-
The artificial pancreas: current status and future prospects in the management of diabetes.Ann N Y Acad Sci. 2014 Apr;1311:102-23. doi: 10.1111/nyas.12431. Ann N Y Acad Sci. 2014. PMID: 24725149 Review.
Cited by
-
Accuracy of Continuous Glucose Monitoring in Hemodialysis Patients With Diabetes.Diabetes Care. 2024 Nov 1;47(11):1922-1929. doi: 10.2337/dc24-0635. Diabetes Care. 2024. PMID: 39213372
-
Scientific Production Dynamics in mHealth for Diabetes: Scientometric Analysis.JMIR Diabetes. 2024 Aug 22;9:e52196. doi: 10.2196/52196. JMIR Diabetes. 2024. PMID: 39172508 Free PMC article.
-
Approaches of wearable and implantable biosensor towards of developing in precision medicine.Front Med (Lausanne). 2024 Jul 18;11:1390634. doi: 10.3389/fmed.2024.1390634. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39091290 Free PMC article. Review.
-
GLP-1 Analogue-Loaded Glucose-Responsive Nanoparticles as Allies of Stem Cell Therapies for the Treatment of Type I Diabetes.ACS Pharmacol Transl Sci. 2024 May 2;7(5):1650-1663. doi: 10.1021/acsptsci.4c00173. eCollection 2024 May 10. ACS Pharmacol Transl Sci. 2024. PMID: 38751616
-
Individualized intensive insulin therapy of diabetes: Not only the goal, but also the time.World J Diabetes. 2024 Jan 15;15(1):11-14. doi: 10.4239/wjd.v15.i1.11. World J Diabetes. 2024. PMID: 38313848 Free PMC article.
References
-
- The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86. - PubMed
-
- Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA. The T1D Exchange clinic registry. J Clin Endocrinol Metab. 2012;97:4383–9. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials